-
Something wrong with this record ?
Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy
GS. Kumar, M. Moustafa, AK. Sahoo, P. Malý, S. Bharadwaj
Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
PubMed
35629327
DOI
10.3390/life12050659
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
Several therapeutic monoclonal antibodies approved by the FDA are available against the PD-1/PD-L1 (programmed death 1/programmed death ligand 1) immune checkpoint axis, which has been an unprecedented success in cancer treatment. However, existing therapeutics against PD-L1, including small molecule inhibitors, have certain drawbacks such as high cost and drug resistance that challenge the currently available anti-PD-L1 therapy. Therefore, this study presents the screening of 32,552 compounds from the Natural Product Atlas database against PD-L1, including three steps of structure-based virtual screening followed by binding free energy to refine the ideal conformation of potent PD-L1 inhibitors. Subsequently, five natural compounds, i.e., Neoenactin B1, Actinofuranone I, Cosmosporin, Ganocapenoid A, and 3-[3-hydroxy-4-(3-methylbut-2-enyl)phenyl]-5-(4-hydroxybenzyl)-4-methyldihydrofuran-2(3H)-one, were collected based on the ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling and binding free energy (>-60 kcal/mol) for further computational investigation in comparison to co-crystallized ligand, i.e., JQT inhibitor. Based on interaction mapping, explicit 100 ns molecular dynamics simulation, and end-point binding free energy calculations, the selected natural compounds were marked for substantial stability with PD-L1 via intermolecular interactions (hydrogen and hydrophobic) with essential residues in comparison to the JQT inhibitor. Collectively, the calculated results advocate the selected natural compounds as the putative potent inhibitors of PD-L1 and, therefore, can be considered for further development of PD-L1 immune checkpoint inhibitors in cancer immunotherapy.
Department of Biology Faculty of Science King Khalid University Abha 62529 Saudi Arabia
Department of Botany and Microbiology Faculty of Science South Valley University Qena 83523 Egypt
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017259
- 003
- CZ-PrNML
- 005
- 20220720100151.0
- 007
- ta
- 008
- 220718s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/life12050659 $2 doi
- 035 __
- $a (PubMed)35629327
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kumar, Geethu S $u Department of Life Science, School of Basic Science and Research, Sharda University, Greater Noida 201310, Uttar Pradesh, India $u Center for Bioinformatics, Computational and Systems Biology, Pathfinder Research and Training Foundation, Greater Noida 201308, Uttar Pradesh, India $1 https://orcid.org/0000000236367918
- 245 10
- $a Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy / $c GS. Kumar, M. Moustafa, AK. Sahoo, P. Malý, S. Bharadwaj
- 520 9_
- $a Several therapeutic monoclonal antibodies approved by the FDA are available against the PD-1/PD-L1 (programmed death 1/programmed death ligand 1) immune checkpoint axis, which has been an unprecedented success in cancer treatment. However, existing therapeutics against PD-L1, including small molecule inhibitors, have certain drawbacks such as high cost and drug resistance that challenge the currently available anti-PD-L1 therapy. Therefore, this study presents the screening of 32,552 compounds from the Natural Product Atlas database against PD-L1, including three steps of structure-based virtual screening followed by binding free energy to refine the ideal conformation of potent PD-L1 inhibitors. Subsequently, five natural compounds, i.e., Neoenactin B1, Actinofuranone I, Cosmosporin, Ganocapenoid A, and 3-[3-hydroxy-4-(3-methylbut-2-enyl)phenyl]-5-(4-hydroxybenzyl)-4-methyldihydrofuran-2(3H)-one, were collected based on the ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling and binding free energy (>-60 kcal/mol) for further computational investigation in comparison to co-crystallized ligand, i.e., JQT inhibitor. Based on interaction mapping, explicit 100 ns molecular dynamics simulation, and end-point binding free energy calculations, the selected natural compounds were marked for substantial stability with PD-L1 via intermolecular interactions (hydrogen and hydrophobic) with essential residues in comparison to the JQT inhibitor. Collectively, the calculated results advocate the selected natural compounds as the putative potent inhibitors of PD-L1 and, therefore, can be considered for further development of PD-L1 immune checkpoint inhibitors in cancer immunotherapy.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Moustafa, Mahmoud $u Department of Biology, Faculty of Science, King Khalid University, Abha 62529, Saudi Arabia $u Department of Botany and Microbiology, Faculty of Science, South Valley University, Qena 83523, Egypt
- 700 1_
- $a Sahoo, Amaresh Kumar $u Department of Applied Sciences, Indian Institute of Information Technology Allahabad, Allahabad 211015, Uttar Pradesh, India
- 700 1_
- $a Malý, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v.v.i., BIOCEV Research Center, 25250 Vestec, Czech Republic $1 https://orcid.org/0000000181180581 $7 xx0128744
- 700 1_
- $a Bharadwaj, Shiv $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v.v.i., BIOCEV Research Center, 25250 Vestec, Czech Republic $1 https://orcid.org/0000000328328617
- 773 0_
- $w MED00186366 $t Life (Basel, Switzerland) $x 2075-1729 $g Roč. 12, č. 5 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35629327 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220718 $b ABA008
- 991 __
- $a 20220720100147 $b ABA008
- 999 __
- $a ind $b bmc $g 1816513 $s 1168501
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 12 $c 5 $e 20220429 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
- LZP __
- $a Pubmed-20220718